Fig. 9
From: Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson’s disease
Effects of combination treatment on abnormal FosB activation in the striatum. Coronal sections showing FosB staining in each group (a). Graph showing altered FosB levels in the HL group compared to the control group and combination treatment group (b). C: control, M: MPTP, K: KD5040, HL: high dose of l -dopa (20 mg/kg). * p < 0.05 vs. control group, ### p < 0.001 and ## p < 0.01 vs. MPTP group, and ††† p < 0.001 vs. each dose of l -dopa. Scale bar: 200 μm